Related Experiment Video
Updated: May 24, 2025

Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins
Published on: January 18, 2019
Anti-nephrin antibody: a potential biomarker of minimal change disease
Qiaoling Chen1,2, Sihui Chen1, Qiuping Ye1,2
1Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.
Background:
Minimal change disease (MCD) is a common pathological type of nephrotic syndrome in children and adults, and the mechanisms remain obscure. The diagnosis of MCD still relies on renal biopsy, lacking effective biological markers. This study explores the diagnostic value of circulating anti-nephrin antibody in MCD patients and evaluates the correlation with disease activity indicators such as proteinuria.
Methods:
The study included 108 adult patients with glomerular disease, including 36 with MCD, 16 with primary focal segmental glomerulosclerosis (FSGS), 20 with primary membranous nephropathy (MN), 17 with diabetic nephropathy (DN) and 19 with immunoglobulin A nephropathy (IgAN). Twenty healthy volunteers were included. Circulating anti-nephrin antibody was detected by indirect immunofluorescence method of cell-based assay. The receiver-operating characteristic (ROC) curve was used to evaluate the role of circulating anti-nephrin antibody in the diagnosis of MCD. The correlations between anti-nephrin antibody and clinical parameters were analyzed.
Results:
The prevalence of circulating anti-nephrin antibody was 19.44% (7 of 36) in MCD and 26.92% (7 of 26) in MCD patients with nephrotic proteinuria, which was higher than in FSGS, PMN, DN, IgAN and healthy volunteers. The ROC curve showed that the sensitivity of anti-nephrin antibody used in the diagnosis of MCD was 19.4% and the specificity was 97.8%. The MCD patients with positive anti-nephrin antibody had heavier proteinuria and higher serum lipid levels, while having lower serum albumin and blood IgG levels. Anti-nephrin antibody might turn to negative when the MCD patient had a response to therapy.
Conclusions:
Circulating anti-nephrin antibody may be a potential biomarker of MCD and may play a role in the MCD diagnosis.
Insights
Circulating anti-nephrin antibody shows promise as a biomarker for minimal change disease (MCD). This antibody may aid in diagnosing MCD and correlating with disease activity, offering a potential alternative to kidney biopsy.
Area of Science:
- Nephrology
- Immunology
- Diagnostic Biomarkers
Background:
- Minimal change disease (MCD) is a primary cause of nephrotic syndrome with unclear pathogenesis.
- Current diagnosis of MCD necessitates invasive renal biopsy, lacking specific biomarkers.
- There is a critical need for reliable diagnostic tools for MCD.
Purpose of the Study:
- To investigate the diagnostic utility of circulating anti-nephrin antibody in minimal change disease (MCD).
- To assess the correlation between anti-nephrin antibody levels and indicators of MCD disease activity.
- To explore the potential of anti-nephrin antibody as a non-invasive biomarker for MCD.
Main Methods:
- Recruited 108 adult patients with various glomerular diseases, including 36 with MCD, and 20 healthy controls.
- Detected circulating anti-nephrin antibody using a cell-based indirect immunofluorescence assay.
- Employed Receiver Operating Characteristic (ROC) curve analysis for diagnostic evaluation and correlated antibody levels with clinical parameters.
Main Results:
- Circulating anti-nephrin antibody was detected in 19.44% of MCD patients, significantly higher than in other glomerular diseases and healthy volunteers.
- ROC analysis indicated a sensitivity of 19.4% and a high specificity of 97.8% for anti-nephrin antibody in diagnosing MCD.
- Positive anti-nephrin antibody correlated with increased proteinuria, elevated serum lipids, and decreased serum albumin and IgG levels, potentially reverting to negative with treatment response.
Conclusions:
- Circulating anti-nephrin antibody demonstrates potential as a valuable biomarker for diagnosing minimal change disease (MCD).
- This antibody may serve as a non-invasive diagnostic marker, aiding in MCD diagnosis and monitoring.
- Further research is warranted to fully elucidate the role of anti-nephrin antibody in MCD pathogenesis and clinical management.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Nephrons

